BioCentury
ARTICLE | Clinical News

Synergy soars on Phase III constipation data

June 18, 2015 12:56 AM UTC

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) jumped $3.14 (68%) to $7.78 after two doses of plecanatide met the primary endpoint of improving the proportion of durable overall responders vs. placebo in a Phase III trial to treat adults with chronic idiopathic constipation (CIC). The company said it plans to file an NDA with FDA in 4Q15 for the guanylate cyclase C ( GCC; GUCY2C) agonist to treat CIC.

Among 1,346 patients in the study's intent-to-treat population, 21% of those receiving 3 mg plecanatide and 19.5% of those receiving 6 mg had durable overall responses to the therapy, compared with 10.2% of those receiving placebo (p<0.001 for both doses). ...